Diagnostic Lab Investment Opportunities in Tampa

The startup is in the pre-revenue, pre-launch stage. - The business is incorporated as a C-Corporation in the State of Delaware, but the acquired laboratory facility is located in Tampa, Florida, where the operations will be based. - One of the two co-founders is currently based in New York, NY, and the other in Chicago, IL. - The co-founders have developed and validated a highly innovative platform technology that enables delivery of a cancer diagnostic test providing therapy guidance across multiple cancer types and treatment modalities, including surgery, radiation, chemotherapy, immunotherapy, and targeted therapy. - The total addressable market (TAM) in the U. S. is approximately $3.6B, with a serviceable available market (SAM) of $2.3B and a serviceable obtainable market (SOM) of $90–116M at full platform scale. - For the U. S. market, the company plans to drive sales and marketing efforts targeting both patients and their physicians. - For international markets, particularly the EU, Latin America, Gulf/MENA, and Southeast Asia, the company intends to engage distribution partners. - In less developed markets, distribution will be managed directly through professional networks and online sales programs targeting patients and physicians. - The co-founder brings extensive experience in life sciences and diagnostics investment banking, having led multiple mergers, acquisitions, and corporate transactions in the diagnostics sector. He is also the architect of the multi-stack AI reporting system that provides a key competitive advantage. - The technical co-founder has over 15 years of experience in NIH-funded cancer research (SBIR Phase I & II awardee) and has developed the core test paradigm and proprietary predictive algorithms that form the foundation of the platform.

The startup is in the pre-revenue, pre-launch stage. - The business is incorporated as a C-Corporation in the State of Delaware, but the acquired laboratory facility is located in Tampa, Florida, where the operations will be based. - One of the two co-founders is currently based in New York, NY, and the other in Chicago, IL. - The co-founders have developed and validated a highly innovative platform technology that enables delivery of a cancer diagnostic test providing therapy guidance across multiple cancer types and treatment modalities, including surgery, radiation, chemotherapy, immunotherapy, and targeted therapy. - The total addressable market (TAM) in the U. S. is approximately $3.6B, with a serviceable available market (SAM) of $2.3B and a serviceable obtainable market (SOM) of $90–116M at full platform scale. - For the U. S. market, the company plans to drive sales and marketing efforts targeting both patients and their physicians. - For international markets, particularly the EU, Latin America, Gulf/MENA, and Southeast Asia, the company intends to engage distribution partners. - In less developed markets, distribution will be managed directly through professional networks and online sales programs targeting patients and physicians. - The co-founder brings extensive experience in life sciences and diagnostics investment banking, having led multiple mergers, acquisitions, and corporate transactions in the diagnostics sector. He is also the architect of the multi-stack AI reporting system that provides a key competitive advantage. - The technical co-founder has over 15 years of experience in NIH-funded cancer research (SBIR Phase I & II awardee) and has developed the core test paradigm and proprietary predictive algorithms that form the foundation of the platform.